Dr. Lee G. Hicks, MD
Hematology & Oncology (Hematology & Oncology Physician)
1720 Nicholasville Rd, Suite #701
Lexington, KY 40503
Who else practices at this address →
Fayette County includes mental health (15% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Louisville School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 307
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: University of Louisville School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KY license 30737
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Lexington Lexington, KY
- Baptist Health Lagrange La Grange, KY
- Baptist Health Richmond Richmond, KY
- Frankfort Regional Medical Center Frankfort, KY
Medical groups
- Baptist Health Medical Group Inc (2,472 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 307
- Services billed
- 801
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 281 | 139 |
| Established patient office or other outpatient visit, 30-39 minutes | 189 | 144 |
| New patient office or other outpatient visit, 60-74 minutes | 61 | 61 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 25 | 16 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 25 | 16 |
| New patient office or other outpatient visit, 45-59 minutes | 24 | 24 |
| Established patient office or other outpatient visit, 20-29 minutes | 23 | 21 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 17 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Lexington, KY | 178 |
| Abiraterone Acetate | 171 |
| Hydroxyurea Other prescribers in Lexington, KY | 143 |
| Prednisone Other prescribers in Lexington, KY | 142 |
| Imbruvica (ibrutinib) | 102 |
| Anastrozole Other prescribers in Lexington, KY | 99 |
| Dexamethasone Other prescribers in Lexington, KY | 86 |
| Calquence (acalabrutinib maleate) | 72 |
| Eliquis (apixaban) Other prescribers in Lexington, KY | 64 |
| Olanzapine Other prescribers in Lexington, KY | 56 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 38 payments worth $797 in total to this clinician.
| Janssen Biotech, Inc. | $100 |
|---|---|
| Pfizer Inc. | $69.00 |
| Gilead Sciences, Inc. | $59.79 |
| Novartis Pharmaceuticals Corporation | $59.05 |
| Astellas Pharma US Inc | $51.36 |
| Ipsen Biopharmaceuticals, Inc | $51.18 |
| AstraZeneca Pharmaceuticals LP | $48.06 |
| Merck Sharp & Dohme LLC | $41.94 |
| Food and Beverage | $797 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $20,985 in research payments for these studies, mostly to the institutions running them.
- A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
Beone Medicines USA, Inc. · Active, not recruiting · NCT05609370 - A phase 3, open-label, randomized study of perioperative dostarlimab m
GlaxoSmithKline, LLC. - An openlabel randomized phase 3 study of tucatinib in combination with trastuzumab and MFOLFOX6 versus MFOLFOX6 given with or without either cetuximab or bevacizumab as firstline treatment for subjects with HER2 metas…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.